Skip to main content
OpenTrials
Completed

NCT Number: NCT05959057

ERr 731® Formulation Evaluation

A comparison of an enteric coated and micro-coated formulation of ERr 731®

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

35 year–64 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Personalized Lifestyle Medicine Center

Gig Harbor, Washington, 98332, United States

About this study

Current clinical and commercialization experiences have been with enteric-coated formulations of ERr 731®. With the demonstrated safety of this formulation and the absence of anthraquinones in the extract, there is interest in launching a micro-coated, but not enteric-coated, formulation to broaden the commercial availability of ERr 731® in new markets. It is proposed that a double-blinded, randomized cross-over design in a peri-menopausal/menopausal and preferably symptomatic group of women (target population for commercialization) is best suited to demonstrate equivalent tolerability.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 35-64, inclusive, preference given to Subjects Ages 45-54, inclusive
  • Preference given to symptomatic Subjects; symptoms including vasomotor symptoms, mood disturbances, fatigue, myalgias and arthralgias.

Exclusion criteria

  • A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic/rheumatological, or oncological/hematologic disease.
  • History of Breast or Uterine cancers.
  • Known infection with HIV, Tuberculosis or Hepatitis B or C.
  • Hormone Replacement Therapy: All formulations of synthetic estrogens, natural estrogens (estrone, estradiol and estriol) and progestins (including natural progesterone)
  • Hormonal Contraceptives: All formulations of synthetic estrogens and progestins
  • Botanical Formulations - including phytoestrogens and progesterone-mimetic botanicals (Rhapontic Rhubarb, Soy Phytoestrogens, Hops (8-prenyl naringin) Red Clover, Kudzu, Chaste Tree Berry, Licorice, Resveratrol, Black Cohosh, Dong Quai, etc.)
  • Use of Narcotics during the last 30 days
  • Use of Anticoagulants during last 30 days
  • Use of Corticosteroids during the last 30 days
  • Use of controlled substances (other than marijuana or CBD) on a recreational basis during the last 30 days.
  • Consumption of more than 3 alcoholic beverages per day (One beverage is a 5-ounce glass of wine, 12 ounces of beer, or one ounce of hard liquor)
  • Pregnancy
  • Breast Feeding

Treatment and study plan

ERr 731 - Micro-coated

Dietary Supplement

natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.

ERr 731 - Enteric coated

Dietary Supplement

natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.

Other names: Estrovera

Primary outcomes

  1. Gastrointestinal Tolerability

    Time frame: 14 days

    Frequency of symptoms of gastrointestinal nature collected on a custom questionnaire

Secondary outcomes

  1. General Tolerability

    Time frame: 14 Days

    Frequency of general symptoms collected on a custom questionnaire

Sponsors and collaborators

Lead sponsor

Metagenics, Inc.

Industry

Registry information

Official study title

ERr 731® Formulation Evaluation: A Comparison of Enteric Coated and Micro-coated ERr 731® Formulations

Acronym: EFE1

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 25, 2023
Registry last updated
Oct 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.